The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma

Leukemia

Volumn 12, Issue 12, 1998, Pages 1971-1976

  Moos, M ^a   Schulz, R ^a   Martin, S ^a   Benner, A ^b   Haas, R ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Blood stem cell transplantation; Minimal disease; Non Hodgkin's lymphoma (NHL); Polymerase chain reaction (PCR); t(14; 18) translocation

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; WHOLE BODY RADIATION;

EID: 0031761395     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401242     Document Type: Article

References (31)

1. Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
2. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
3. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
4. Haas R, Möhle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
5. Langlands K, Anderson JS, Parker AC, Anthony RS. Polymerase chain reaction analysis of tumor contamination in peripheral blood stem cell harvests. Int J Cell Clon 1992; 10: 95-97.
6. Sharp JG, Kessinger A, Vaughan WP, Mann S, Crouse DA, Dicke K, Masih A, Weisenburger DD. Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Clon 1992; 10: 92-94.
7. Brugger W, Brass KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
8. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225-232.
9. Craig JIO, Langlands K, Parker AC, Anthony RS. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994; 22: 898-902.
10. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
11. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
12. Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, Yeap B, Soiffer R, Coral FC, Heflin L, Ritz J, Nadler LM. Autologous bone marrow transplantation in B cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-791.
13. Yunis JJ, Oken MM, Kaplan ME, Theologides RR, Howe A. Distinctive chromosomal abnormalities in histologic subtypes of nonHodgkin's lymphoma. New Engl J Med 1982; 307: 1231-1236.
14. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood 1985; 6: 1414-1422.
15. Ott MM, Müller-Hermelink HK, Schmitt B, Feller AC. Chromosomal translocation detected by bcl-1 and bcl-2 rearrangement in low-grade B cell lymphomas in a European population. Histopathology 1991; 19: 163-167.
16. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on chromosome 18. Cell 1985; 41: 899-906.
17. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19-28.
18. Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996; 17: 149-155.
19. Haas R, Moos M, Karcher A, Möhle R, Witt B, Goldschmidt H, Frühauf S, Flentje M, Wannenmacher M, Hunstein W. Sequential high-dose therapy with peripheral blood progenitor cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12-1685-1692.
20. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM. Immunologic purging of marrow assesed by PCR before ABMT for B cell lymphoma. New Engl J Med 1991; 323: 1525-1533.
21. Sanger F, Nicklem S, Coulson AR. DNA sequencing with chain termination inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
22. Andersen P, Gill R. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 1100-1120.
23. Cox DR. Regression models and life-tables. J Roy Stat Soc Ser B 1972; 34: 187-220.
24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.
25. Hardingham JE, Kotasek D, Sage RE, Dobrovic A, Gooley T, Dale BM. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993; 11: 15-20.
26. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, Pileri A, Tarella C. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
27. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
28. Hardingham JE, Kotasek D, Sage RE, Gooley LT, Mi J-X, Dobrovic A, Norman JE, Bolton AE, Dale BM. Significance of molecular marker-positive cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 1073-1079.
29. Maloney DC, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
30. Hiddemann W, Unterhalt M, Buske C, Sack H. Treatment of follicular follicle centre lymphomas: current status and future perspectives. J Intern Med Suppl 1997; 740: 55-62.
31. Johnson PWM, Price CGA, Smith T, Cotter FE, Meerabux J, Rohatiner AZS, Young BD, Lister TA. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798-805.